Radiation dosimetry of <sup>18</sup>F-AzaFol: A first in-human use of a folate receptor PET tracer.

Details

Ressource 1Download: 32270313_BIB_E6CC33686BEF.pdf (1908.60 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_E6CC33686BEF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Radiation dosimetry of <sup>18</sup>F-AzaFol: A first in-human use of a folate receptor PET tracer.
Journal
EJNMMI research
Author(s)
Gnesin S., Müller J., Burger I.A., Meisel A., Siano M., Früh M., Choschzick M., Müller C., Schibli R., Ametamey S.M., Kaufmann P.A., Treyer V., Prior J.O., Schaefer N.
ISSN
2191-219X (Print)
ISSN-L
2191-219X
Publication state
Published
Issued date
08/04/2020
Peer-reviewed
Oui
Volume
10
Number
1
Pages
32
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
The folate receptor alpha (FRα) is an interesting target for imaging and therapy of different cancers. We present the first in-human radiation dosimetry and radiation safety results acquired within a prospective, multicentric trial (NCT03242993) evaluating the <sup>18</sup> F-AzaFol (3'-aza-2'-[ <sup>18</sup> F]fluorofolic acid) as the first clinically assessed PET tracer targeting the FRα.
Six eligible patients presented a histologically confirmed adenocarcinoma of the lung with measurable lesions (≥ 10 mm according to RECIST 1.1). TOF-PET images were acquired at 3, 11, 18, 30, 40, 50, and 60 min after the intravenous injection of 327 MBq (range 299-399 MBq) of <sup>18</sup> F-AzaFol to establish dosimetry. Organ absorbed doses (AD), tumor AD, and patient effective doses (E) were assessed using the OLINDA/EXM v.2.0 software and compared with pre-clinical results.
No serious related adverse events were observed. The highest AD were in the liver, the kidneys, the urinary bladder, and the spleen (51.9, 45.8, 39.1, and 35.4 μGy/MBq, respectively). Estimated patient and gender-averaged E were 18.0 ± 2.6 and 19.7 ± 1.4 μSv/MBq, respectively. E in-human exceeded the value of 14.0 μSv/MBq extrapolated from pre-clinical data. Average tumor AD was 34.8 μGy/MBq (range 13.6-60.5 μGy/MBq).
<sup>18</sup> F-Azafol is a PET agent with favorable dosimetric properties and a reasonable radiation dose burden for patients which merits further evaluation to assess its performance.
ClinicalTrial.gov, NCT03242993, posted on August 8, 2017.
Keywords
Radiology Nuclear Medicine and imaging, 18F-Azafol, Choroid plexuses, Dosimetry, FOLR1, FRalpha, FRα, Folate receptor, Imaging, Lung cancer, OLINDA/EXM, Positron emission tomography (PET)
Pubmed
Web of science
Open Access
Yes
Create date
21/04/2020 9:18
Last modification date
15/01/2021 7:12
Usage data